Compumedics (ASX:CMP) secured multiple Somfit sales to US-based pharmaceutical contract research organization and Finland-based Orion Pharma, with nearly $2 million of combined revenues from initial transactions, according to a Monday filing with the Australian bourse.
Somfit is a wearable home sleep test device designed to help diagnose sleep-related breathing disorders.
The first transaction involved a clinical drug trial facilitated by the contract research organization in the US, and the second involved the deployment of Somfit in a multi-country, multi-center clinical study across Europe, the filing said.
Shares fell more than 1% in midday trade Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。